Evidence map›Paper›PMID 40441891›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

[

David M L Lilburn, Helen S Garthwaite, Balaji Ganeshan, Thida Win, Nicholas J Screaton, Luke R Hoy, Darren Walls, Raymond Endozo, Robert I Shortman, Francesco Fraioli and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Pulmonary [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Molecular imaging of fibroblast activation in systemic sclerosis using [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

David M L LilburnInstitute of Nuclear Medicine, University College London Hospital, London, United Kingdom.
Helen S GarthwaiteInterstitial Lung Disease Service, Department of Respiratory Medicine, University College London Hospital, London, United Kingdom.
Balaji GaneshanInstitute of Nuclear Medicine, University College London Hospital, London, United Kingdom.
Thida WinRespiratory Medicine Department, Lister Hospital, Stevenage, United Kingdom.
Nicholas J ScreatonRadiology Department, Papworth Hospital, Cambridge, United Kingdom.
Luke R HoyInstitute of Nuclear Medicine, University College London Hospital, London, United Kingdom.
Darren WallsInstitute of Nuclear Medicine, University College London Hospital, London, United Kingdom.
Raymond EndozoInstitute of Nuclear Medicine, University College London Hospital, London, United Kingdom.
Robert I ShortmanInstitute of Nuclear Medicine, University College London Hospital, London, United Kingdom.
Francesco FraioliInstitute of Nuclear Medicine, University College London Hospital, London, United Kingdom.
Athol U WellsInterstitial Lung Disease Unit, Royal Brompton Hospital, National Heart and Lung Institute, Imperial College, London, United Kingdom.
Christopher P DentonCentre for Rheumatology, Division of Medicine, University College London, London, United Kingdom; and.
Ashley M GrovesInstitute of Nuclear Medicine, University College London Hospital, London, United Kingdom; ashleygroves@nhs.net.
Joanna C PorterInterstitial Lung Disease Service, Department of Respiratory Medicine, University College London Hospital, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are few effective prognostic biomarkers in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). We investigated the potential of [

Indexed as

Fluorodeoxyglucose F18Lung Diseases, InterstitialPositron Emission Tomography Computed TomographyScleroderma, SystemicAgedFemaleHumansMaleMiddle AgedPrognosisRadiopharmaceuticalsSurvival AnalysisFluorodeoxyglucose F18RadiopharmaceuticalsKaplan–Meier survivalPET/CTsex-age-physiology scoresystemic sclerosis–associated interstitial lung disease

Identifiers

PMID40441891
PMCPMC12212404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.